Hoth Therapeutics Inc (HOTH) - Total Liabilities
Based on the latest financial reports, Hoth Therapeutics Inc (HOTH) has total liabilities worth $1.43 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hoth Therapeutics Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Hoth Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Hoth Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.
Hoth Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Hoth Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mon Courtier Energie Groupe SA
PA:ALMCE
|
France | €12.49 Million |
|
Mycron Steel Bhd
KLSE:5087
|
Malaysia | RM163.95 Million |
|
Inception Growth Acquisition Ltd
NASDAQ:IGTA
|
USA | $7.15 Million |
|
Brooks Laboratories Limited
NSE:BROOKS
|
India | Rs242.82 Million |
|
STAK Inc. Ordinary Shares
NASDAQ:STAK
|
USA | $13.85 Million |
|
Schlatter Industries AG
SW:STRN
|
Switzerland | CHF43.72 Million |
|
Nucletron Electronic Aktiengesellschaft
F:NUC
|
Germany | €2.08 Million |
|
Ikonisys SA
PA:ALIKO
|
France | €7.50 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Hoth Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Hoth Therapeutics Inc (HOTH) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hoth Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hoth Therapeutics Inc (2017–2025)
The table below shows the annual total liabilities of Hoth Therapeutics Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.45 Million | +74.20% |
| 2024-12-31 | $833.91K | +18.29% |
| 2023-12-31 | $704.98K | -56.95% |
| 2022-12-31 | $1.64 Million | +48.51% |
| 2021-12-31 | $1.10 Million | +84.68% |
| 2020-12-31 | $597.15K | +35.68% |
| 2019-12-31 | $440.12K | +26.13% |
| 2018-12-31 | $348.95K | +605.44% |
| 2017-12-31 | $49.47K | -- |
About Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to … Read more